Oaktree Acquisition Corp. III Life Sciences Q2 2026 Earnings Report

Oaktree Acquisition Corp. III Life Sciences EPS Results

• Actual EPS: $0.07
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Oaktree Acquisition Corp. III Life Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oaktree Acquisition Corp. III Life Sciences Announcement Details

• Quarter: Q2 2026
• Date: 8/12/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) (NASDAQ: OACC) is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with a company in the life sciences sector.

The company does not operate as a traditional commercial business and does not manufacture or sell products or provide healthcare services. Instead, its activities are focused on evaluating potential merger, acquisition, or other business combination opportunities involving businesses such as biotechnology, pharmaceuticals, medical devices, diagnostics, and related healthcare industries.

Oaktree Acquisition Corp. III Life Sciences is affiliated with Oaktree Capital Management, an investment management firm. Publicly available information about the company’s operating activities, geographic reach, and leadership is limited because its primary purpose is to pursue a transaction rather than conduct an established operating business.